JAK inhibitors

Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
Tofacitinib INTRODUCTION Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
Tofacitinib
Diagnosing & Treating Vitiligo in 2022 and What’s To Come
vitiligoAs a former vitiligo clinical trials research fellow, I have attended more than my fair share of presentations on vitiligo. Yet, I am amazed at how each additional lecture continues to teach me new and exciting concepts and treatment options for vitiligo. Dr. Seemal Desai’s lecture at the 2022 Skin of Color Update Conference was no exception to this rule. During the SOCU Conference held in Ne …
vitiligo
Upadacitinib Therapeutic Cheat Sheet
UpadacitinibUpadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat  rheumatoid arthritis and psoriatic arthritis, but  was recently FDA approved i …
Upadacitinib
Oral Minoxidil for Hair Loss | The Expert Weighs In
oral minoxidil for hair lossINSIDER recently posted an article on oral minoxidil for hair loss as a result of media coverage in The New York Times. Which hair loss patients make good candidates for oral minoxidil? How should a dermatologist determine the best dosage for their patients? For expert advice, I reached out to Shilpi Khetarpal, MD, FAAD, director of cosmetic dermatology and lasers at the Cleveland Clinic. …
oral minoxidil for hair loss
Atopic Dermatitis (AD) Treatment Initiation and Monitoring
atopic dermatitis (AD)During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.  CASE 1 51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA …
atopic dermatitis (AD)